Efficacy and safety of pro re nata regimen without loading dose ranibizumab injections in retinal vein occlusion

Pakistan Journal of Medical Sciences

Volumn 31, Issue 3, 2015, Pages 510-515

  Unsal, Erkan ^a   Eltutar, Kadir ^a   Sultan, Pınar ^a   Gungel, Hulya ^a  

^a ISTANBUL TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Macular thickness; Ranibizumab; Retinal Vein Occlusion

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL MACULAR THICKNESS; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CONJUNCTIVAL HEMORRHAGE; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; MACULAR EDEMA; MALE; RETINA DETACHMENT; RETINA VEIN OCCLUSION; RETROSPECTIVE STUDY; VISUAL ACUITY; VITREOUS HEMORRHAGE;

EID: 84929576355     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: 10.12669/pjms.313.7218     Document Type: Article

References (23)

1. Greer DV, Constable IJ, Cooper RL. Macular oedema and retinal branch vein occlusion. Aust J Ophthalmol. 1980;8(3):207-209.
2. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular oedema in branch vein occlusion. Am J Ophthalmol. 1984;98(3):271-282.
3. The Central Vein Occlusion Study Group.: M report. Evaluation of grid pattern photocoagulation for macular oedema in central vein occlusion. Ophthalmology. 1995;102(10):1425-1433.
4. Central Vein Occlusion Study Group M report. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology. 1995;102(10):1425-1433.
5. Noma H, Minamoto A, Funatsu H, Tsukamoto H, Nakano K, Yamashita H, et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2006;244(3):309-315. doi: 10.1007/s00417-004-1087-4.
6. Rehak J, Rehak M. Branch Retinal Vein Occlusion: Pathogenesis, Visual Prognosis, and Treatment Modalities. Curr Eye Res. 2008;33(2):111-131. doi: 10.1080/02713680701851902.
7. Eken V, Batıoglu F, Ozmert E. Efficacy of Intravitreal Ranibizumab (Lucentis®) injection for the treatment of macular edema secondary to retinal vein occlusion. Ret-Vit. 2011;19(2):108-112.
8. Sophie R, Hafiz G, Scott AW, Zimmer-Galler I, Nguyen QD, Ying H, et al. Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion. Am J Ophthalmol. 2013;156(4):693-705. doi: 10.1016/j.ajo.2013.05.039.
9. Campochiaro PA. Anti-vascular endothelial growth factor treatment for retinal vein occlusions. Ophthalmologica. 2012;227(Suppl 1):30-35. doi: 10.1159/000337157.
10. Ozmen MC, Ozdek Ş. Recent Treatment Modalities For Macular Edema Secondary to Retinal Vein Occlusions. Ret-Vit. 2008;16(1):1-8.
11. Green WR. Retinal ischemia: Vascular and circulatory conditions and diseases.In: Spencer WH, eds. Ophthalmic Pathology. Philadelphia: W.B. Saunders Company. 1985. p.655-710.
12. Lang GE, Freissler K. Clinical and fluorescein angiography findings in patients with retinal vein occlusion. A unicenter study of 211 patients. Klin Monatsbl Augenheilkd. 1992;201(4):234–239.
13. Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM. Prognostic factors for retinal vein occlusion: prospective study of 175 cases. Ophthalmology. 1996;103(4):551-560.
14. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134–1146. doi: 10.1016/j.ophtha.2010.03.032.
15. McIntosh RL, Mohamed Q, Saw SM, Wong TY. Interventions for Branch Retinal Vein Occlusion: An Evidence-Based Systematic Review. Ophthalmology. 2007;114(4):835-854. doi: 10.1016/j.ophtha.2007.01.010
16. Garnock-Jones KP. Ranibizumab: in macular oedema following retinal vein occlusion. Drugs. 2011;71(4):455-463. doi: 10.2165/11206900-000000000-00000.
17. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011;118(8):1594–1602. doi: 10.1016/j.ophtha.2011.02.022.
18. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118(10):2041–2049. doi: 10.1016/j.ophtha.2011.02.038.
19. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119(4):802–809. doi: 10.1016/j.ophtha.2011.12.005.
20. Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol. 2009;147(2):298-306. doi: 10.1016/j.ajo.2008.08.016.
21. Kinge B, Stordahl PB, Forsaa V, Fossen K, Haugstad M, Helgesen OH, et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. Am J Ophthalmol. 2010;150(3):310–314. doi: 10.1016/j.ajo.2010.03.028.
22. Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, A Heier, et al. RETAIN Study Group. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 2014;121(1):209-219. doi: 10.1016/j.ophtha.2013.08.038.
23. Kim YJ, Sung KR, Lee KS, Joe SG, Lee JY, Kim JG, et al. Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure. Am J Ophthalmol. 2014;157(6):1266-1271. doi: 10.1016/j.ajo.2014.02.035